Enliven Therapeutics (ELVN) Current Leases (2021 - 2026)
Enliven Therapeutics' (ELVN) quarterly Current Leases came in at $302000.0 in Q1 2026, down 17.26% year-on-year from $365000.0 in Q1 2025, and down 24.31% quarter-over-quarter from $399000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Current Leases (2021 - 2026) Analysis & Trends
Enliven Therapeutics has disclosed Current Leases across 6 years of filings, most recently posting $302000.0 for Q1 2026.
- Current Leases for Q1 2026 came in at $302000.0, down 17.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $302000.0 (down 17.26% YoY), and the FY2025 annual result was $399000.0, changed N/A from the prior year.
- Current Leases came in at $302000.0 for Q1 2026 at Enliven Therapeutics, down from $399000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $508000.0 in Q1 2022 to a low of $85000.0 in Q3 2024.
- The 5-year median for Current Leases is $333500.0 (2023), against an average of $329071.4.
- Across the five-year window, Current Leases plunged 74.4% in 2024 and jumped 355.29% in 2025, its largest moves.
- Enliven Therapeutics' Current Leases stood at $323000.0 in 2022, then rose by 3.72% to $335000.0 in 2023, then slumped by 74.63% to $85000.0 in 2024, then jumped by 369.41% to $399000.0 in 2025, then dropped by 24.31% to $302000.0 in 2026.
- The last three Current Leases figures came in at $302000.0 (Q1 2026), $399000.0 (Q4 2025), and $387000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - | 302,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 302,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | 365,000.00 |
| Sep 30, 2024 | 85,000.00 |
| Jun 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Sep 30, 2023 | 332,000.00 |
| Jun 30, 2023 | 329,000.00 |
| Dec 31, 2022 | 323,000.00 |
| Jun 30, 2022 | 445,000.00 |
| Mar 31, 2022 | 508,000.00 |
| Dec 31, 2021 | 246,000.00 |
| Sep 30, 2021 | 250,000.00 |
| Jun 30, 2021 | 254,000.00 |
| Mar 31, 2021 | 257,000.00 |